Alexion Pharmaceuticals Inc. (ALXN) Release: European Commission (EC)Grants Orphan Drug Designation To Soliris® (Eculizumab) For Prevention Of Delayed Graft Function (DGF) After Solid Organ Transplantation
2/24/2014 8:11:07 AM
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris® (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function (DGF) after solid organ transplantation. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation. In patients undergoing kidney transplantation, patients who develop DGF require dialysis in order to survive. 1-3
Help employers find you! Check out all the jobs and post your resume.
comments powered by